Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05056727 · ClinicalTrials.gov registry record · Phase 3
A Study to Evaluate the Effect of Sodium Zirconium Cyclosilicate on Chronic Kidney Disease (CKD) Progression in Participants With CKD and Hyperkalaemia or at Risk of Hyperkalaemia
A Phase 3 study, sponsored by AstraZeneca.
- Terminated
- Registry status
- Phase 3
- Development phase
- 1,112
- Enrollment target
NCT05056727 is a Phase 3 study that was terminated before completion, run by AstraZeneca. The registered enrollment target is 1,112 participants.
The verdict
NCT05056727, a Phase 3 study, was terminated before completion, sponsored by AstraZeneca.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 1,112 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the effect of Sodium Zirconium Cyclosilicate (SZC), as adjunct to ACEi/ARB therapy (lisinopril or valsartan), on slowing CKD progression (assessed as the reduction in participant's glomerular filtration rate \[eGFR\] decline over time) in participants with hyperkalaemia or at high risk of hyperkalaemia.
Interventions
- DRUG Placebo
- DRUG Valsartan
- DRUG Irbesartan
- DRUG Lisinopril
- DRUG Sodium Zirconium Cyclosilicate (SZC)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,112 participants |
| Start Date | 2021-09-30 |
| Est. Completion | 2024-02-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05056727
The ClinicalTrials.gov registry entry for NCT05056727 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 1,112 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Placebo is the first listed.
NCT05056727 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05056727 about?
NCT05056727 is a clinical study titled "A Study to Evaluate the Effect of Sodium Zirconium Cyclosilicate on Chronic Kidney Disease (CKD) Progression in Participants With CKD and Hyperkalaemia or at Risk of Hyperkalaemia". The purpose of this study is to evaluate the effect of Sodium Zirconium Cyclosilicate (SZC), as adjunct to ACEi/ARB therapy (lisinopril or valsartan), on slowing CKD progression (assessed as the reduction in participant's glomerular filtration rate \[eGFR\] decline over time) in participants with hy...
What is the current status of trial NCT05056727?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 1,112 participants. The study started on 2021-09-30. Estimated completion is 2024-02-07.
What interventions are being tested in trial NCT05056727?
The interventions under investigation include: Placebo (DRUG), Valsartan (DRUG), Irbesartan (DRUG), Lisinopril (DRUG), Sodium Zirconium Cyclosilicate (SZC) (DRUG).
Who is sponsoring clinical trial NCT05056727?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.